Comparing a new drug to standard chemo for B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests if a new drug, RDC-Blinatumomab, works better than the usual chemotherapy (hyperCVAD) for people with a type of leukemia called Ph-negative B-ALL. It is for newly diagnosed patients who haven't had other treatments yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 15 and 65 years old.
- You must have a specific type of leukemia called Ph-negative B-ALL.
- You must be newly diagnosed and have not received prior treatment except for up to 5 days of certain medicines.
- Your overall health must allow you to be active (ECOG score 0-3).
- Your liver and kidney function must be within certain limits.
- You cannot have other serious conditions like HIV, active hepatitis, or heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted drug (blinatumomab) with a lower dose of standard chemotherapy for adults newly diagnosed with a certain type of B-cell acute lymphoblastic leukemia. The goal is to see if this approach is effective and causes fewer side effects than full-dose chemotherapy.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
This study tests a new treatment for adults newly diagnosed with a type of leukemia called B-ALL. It uses a lower dose of chemotherapy followed by a 14-day course of blinatumomab, which helps the immune system fight cancer cells. This approach may reduce side effects while still being effective.
This study tests a new injectable drug called BLB101 compared to a standard treatment (Blincyto) for adults with a type of leukemia called B-ALL that has come back or not responded to treatment. It may help you if your leukemia has the CD19 protein and you have had 1 to 2 previous treatments.
Hear when a new ALL, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.